Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2001

View Archived Issues

GSK issues product pipeline update

Biomira suspends two cancer vaccine programs to focus on advanced products

Dalbavancin to be developed as the first once-weekly injectable antibiotic

Lymphatic agent Tc-mannosyl-dextran undergoes clinical study in melanoma patients

Dyax acquires exclusive rights to develop antibody drugs aimed at angiogenesis target

Age limit lowered for participation in phase II trial of tgAAVCF in cystic fibrosis

Zenapax enters phase II trial in patients with chronic asthma

Prescient NeuroPharma and Access Oncology sign letter of intent for anhydrovinblastine

DMXAA increases the antitumor effect of radiotherapy and exerts antitumor activity on its own

Medicure seeks phase II clearance in U.S. and Canada for MC-1

Canadian approval for Fludara as NHL treatment

SB-265610: a nonpeptide CXCR2 antagonist effective against neutrophil accumulation

Class III antiarrhythmics from Merck KGaA prolong APD by blocking rapid delayed rectifier current

Synthetic heat shock protein-derived peptide appears to arrest progression of type 1 diabetes

Active vaccination against IL-5 as a novel approach to asthma

FDA marketing approval granted for improved form of Ritalin for ADHD

First IL-1 receptor antagonist now available for treatment of rheumatoid arthritis

Ivax immunotoxin for brain cancer reportedly effective at very low intratumoral doses

Geron telomerase inhibitor effective against particularly aggressive human tumors in mice

FDA clears injectable antibiotic Invanz

Novel compounds for CNS disorders, including stroke and ALS

Blood glucose-lowering glycosides designed by Kotobuki

Isoquinoline series with agonist activity at beta3-adrenoceptors

Nippon Kayaku isolates antitumor substances from Streptomyces

New MCP-1 receptor antagonists and uses thereof claimed by Daiichi

3-D presents thiazole-based PAI-1 inhibitors

Banyu patents selective muscarinic M3 receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...